SS Innovations International (NASDAQ: SSII) reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year, driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system to 30 units. The company's gross profit climbed 20% to $7.1 million, yielding a gross margin of 50.9%. Despite a net loss of $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million a year earlier, the company's first-half revenue surged 65.6% to $25 million, with installations up 47.4% to 56.
As of June 30, SS Innovations held $13.6 million in cash and cash equivalents, with no long-term debt, and a cumulative installed base of 224 SSi Mantra systems across 12 countries. The company reported 12,272 cumulative procedures using the SSi Mantra, including 175 telesurgeries. Notably, it completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's remote capabilities.
Regulatory progress is a key focus. SS Innovations expects the U.S. Food and Drug Administration (FDA) to complete its review of the company's 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027, and it believes it can obtain European Union CE marking certification by the end of 2026. These milestones are critical for expanding into major markets and could significantly boost adoption.
The company's growth trajectory and regulatory advancements signal its commitment to making robotic surgery affordable and accessible globally. With a strong cash position and no debt, SS Innovations is well-positioned to navigate the regulatory landscape and capitalize on the increasing demand for minimally invasive surgical technologies. The successful telesurgery also highlights the potential for remote surgical procedures, which could revolutionize healthcare delivery in underserved regions.
Investors and industry observers will be watching closely as the company approaches these regulatory deadlines. The outcomes will likely influence the company's market penetration and competitive standing in the surgical robotics sector. For more details, visit the original press release at https://ibn.fm/nTMso.
